National and Kapodistrian University of Athens
Tools for accelerating the development of amorphous drug solid dispersions: case example, tacrolimus
Abstract
dc:descriptionThe need for bio-enabling formulations is derived from the fact that in recent years, industry pipelines are increasingly populated by active pharmaceutical ingredients (APIs) with substantial solubility issues. Management of the low luminal solubility of emerging APIs is prerequisite for successful absorption after oral administration. A variety of approaches have been proposed including the use of lipid-based formations, cyclodextrins and amorphous solid dispersions. Amorphous solid dispersions (ASDs) have gained wide acceptance due to their versatile use, as since their introduction they have evolved from simple eutectic mixtures to complex systems with modified release characteristics. ASDs exhibit the ability to increase the apparent solubility of APIs in the gut lumen by allowing the delivery of the API in a high energy form, most frequently, in the amorphous state. However, a high energy form is metastable and its inherent propensity for crystallization requires the use of excipients to maintain the amorphous state. This is, routinely, facilitated by the use of polymers, which can stabilize the amorphous state of the API by specific API-polymer interactions, by exhibiting an anti-plasticization effect, by kinetically trapping the API in the polymer chains and by enabling molecular dispersion of the API in the matrix. Consequently, for successful ASDs an API-polymer miscible combination needs to be established. Finding an appropriate API-polymer combination could be found on a trial and error basis. Because relevant investigations are time and resource consuming, usually simple, in silico thermodynamic tools, such as the Flory-Huggins interaction parameter and the Hansen solubility parameters’ calculations are used. These are widely used tools that have, however, been criticized for some conceptual limitations. In addition, it is also accepted that even though the experimental determination of solubility parameters would provide a more robust set of information regarding API-polymer miscibility, it is a strenuous and sophisticated process. Another, obstacle in the development of ASDs is the difficulty in evaluating their luminal performance prior to their administration to humans and/or the poor correlation they exhibit between their in vitro dissolution and in vivo performance. Unlike with conventional drug products, various API and polymer species arise during the dissolution process, ranging from amorphous API and crystalline precipitate to colloidal structures that can act as API depotsThe aim of this work was to provide new tools for facilitating the development of ASDs, by addressing two important bottlenecks in the process; (1) the prediction of miscible API-polymer combinations and (2) the in vitro evaluation of the luminal performance of ASDs. We tackled each problem by using tacrolimus as a model API, which has low solubility and erratic absorption characteristics. We screened polymers on the basis for their miscibility with tacrolimus, prepared tacrolimus ASDs with the proposed miscible polymers and we investigated the usefulness of biorelevant in vitro testing in evaluating the impact of formulation on the in vivo performance of tacrolimus ASD products with modified release characteristics on an a priori basis (before the in vivo data were available). Initially, a novel, easy to apply and theory-based methodology was investigated for its usefulness in determining tacrolimus-polymer miscibility, using 6 polymer candidates with varying physicochemical characteristics. The method is based on rheology measurements of API-polymer blend solutions at the theoretical point of infinite dilution, which are used in order to acquire interaction parameters that have been correlated with the miscibility potential of two systems. Predictions of miscible tacrolimus-polymer combinations based on this methodology were contrasted with the miscibility predictions based on calculated Hansen solubility parameters. Both predictions were, subsequently, evaluated based on data collected from the physical state monitoring of prepared tacrolimus solid dispersions. It was shown that the rheology-based method exhibits increased predictive power compared to the calculated Hansen solubility parameters. This was in part attributed to the fact that Hansen solubility parameters take into account mainly structure specific input and fail to interpret other aspects of miscibility, such as viscosity, crystallinity etc. Based on data from this study with tacrolimus ASDs, the rheology-based methodology is a reliable and easily accessible methodology for miscibility investigations, at the early stages of ASD development. Three polymers which were shown to be miscible with tacrolimus (low substituted hydroxypropoyl cellulose (HPC-L), ethyl cellulose (EC), Eudragit® S100) were used for preparing novel tacrolimus ASDs with modified release characteristics. Relevant tacrolimus ASDs were prepared using two drug loadings, two surfactants, two surfactant ratios, and two modes of surfactant incorporation in the ASDs. After preparation and storage, tacrolimus was shown to be present in an amorphous state, in all cases. Subsequently, tablet dose units (novel tacrolimus products) were prepared. Based on data collected in an aqueous environment used for evaluating potential formulation effects on tacrolimus release behavior, the low-loaded tacrolimus products failed to release the dose and were not considered further. The tacrolimus products with HPC-L showed rapid disintegration, despite the polymer’s hydrophobic and swellable nature, thus not exhibiting a modified release character and, therefore, were also not considered further. The 8 most promising tacrolimus product candidates were investigated under biorelevant conditions using the compendial apparatus IV. In this set-up, the two commercially available tacrolimus ASD formulations, Advagraf® and Envarsus®, were also investigated. A novel tacrolimus product with modified release characteristics, clearly different from those of Advagraf® and Envarsus® was investigated in an in vivo study in healthy adults in comparison to Advagraf® and Envarsus®. Based on the in vivo data, the in vitro biorelevant data correctly predicted differences in early exposure between Advagraf® and the novel tacrolimus product, thus confirming previous findings on the limited usefulness of compendial apparatus IV for monolithic drug products with shear stress dependent release behavior. Using tacrolimus as model API in this thesis, a workflow that could facilitate the development of new ASDs was proposed, by introducing a rheology-based methodology for the estimation of drug-polymer miscibility at the pre-formulation stage along with a stepwise investigation of the effect of formulation choices on the dissolution of the ASDs in vivo.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsakiridou, Georgia
- Τσακιρίδου, Γεωργία
Subjects
dc:subject × 12Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/47762